@article{c107dc4679694347a2b7000ac163895e,
title = "Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study",
abstract = "Purpose: To investigate (in a post hoc analysis of the 2-year CONDUCT study) the characteristics and clinical outcomes of men with moderately symptomatic benign prostatic hyperplasia (BPH) at risk of progression who benefitted from lifestyle changes alone. Methods: Patients were given lifestyle advice and randomized to a fixed-dose combination (FDC) of dutasteride and tamsulosin or watchful waiting (WW) and followed for 24 months. Patients in the WW group were escalated to tamsulosin if any follow-up International Prostate Symptom Score (IPSS) was equal or greater than the baseline value. Improvements in symptoms (change in IPSS) and quality of life [measured by BPH Impact Index (BII) and question 8 of the IPSS (IPSS-Q8)] were analysed in the FDC group, men who initiated tamsulosin (WW-TAM) and men who received no medical intervention (WW-no treatment) and the impact of baseline variables on IPSS determined. Results: The adjusted mean decrease in IPSS, BII and IPSS-Q8 at each post-baseline visit over 24 months appeared greater in the FDC (n = 369) and WW-no treatment groups (n = 144) than in the WW-TAM group (n = 229). IPSS improvements appeared similar in the FDC group and WW-no treatment subgroup, except in patients with the greatest degree of bother at baseline (BII 7–13). Conclusion: BII at baseline may be a more relevant indicator than symptom severity as to whether a patient with moderate symptoms should receive medical therapy or not.",
keywords = "BPH Impact Index, Benign prostatic hyperplasia, Dutasteride, Lower urinary tract symptoms, Tamsulosin, Watchful waiting",
author = "Claus Roehrborn and {Oyarzabal Perez}, Igor and Roos, {Erik P M} and Nicolae Calomfirescu and Betsy Brotherton and Palacios, {Juan Manuel} and Averyan Vasylyev and Manyak, {Michael J.}",
note = "Funding Information: Medical writing support was provided by Spirit Medical Communications, funded by GlaxoSmithKline. The authors thank the following investigators and their patients for participating in the study. France: Abdel-Rahm{\`e}ne Azzouzi, Alain Boye, Christian Duroy, Daniel Bonneau, Gildas Ganuchaid, Gwendal Hulot De Collart, Jacques Tondut, Jean-Marc Aroun, J{\'e}r{\^o}me Basle, J{\'e}r{\^o}me Tondut, Lo{\"i}c Boucher, Michel Lambert, Nicolas Tournemine, Patrick Muller, Philippe Igigabel, Pierre Leroy, Pierre Andr{\'e} Ferrand, Robert Arnou, Thierry Schaupp. Germany: Christian Girke, Christian von Ostau, Detlef Quast, Hans-Carsten Braun, Joachim Dubiel, Joerg Willgerodt, Klaus Scheunpflug, Maren Schwickardi-Jerrentrup, Rainer Klammert, Ralk Eckert, Tilo Koettig, Wolf-Christian Hagel, Wolfgang Warnack. Greece: Anastasios Thanos, Andreas Skolarikos, Apostolos Apostolidis, Athanasios Papathanasiou, Georgios Moutzouris, Harilaos Katsifotis, Michael Melekos, Nikolaos Papandreou, Panagiotis Kalafitis, Pteros Perimenis. Italy: Cesare Selli, Francesco Montorsi, Giuseppe Carrieri, Luigi Schips, Mauro Frongia, Paolo Gontero, Vincenzo Gentile, Vincenzo Mirone, Virgilio Cicalese. The Netherlands: Arnoldus G.H. Geboers, Hendrik A. Dirkse, Hendrikus G.M. Mevissen, Jos L. Bruins. Romania: Ioan Ioiart, Marius Dinu, Viorel Jinga. Spain: Javier Angulo Cuesa, Javier Extraniana, Javier Garcia Penit, Jose Martinez Javaloyas, Jos{\'e} A. Gallego S{\'a}nchez, Jos{\'e} Mar{\'i}a Del Rosal Samaniego, Maria Jose Requena Tapia, Manuel Fern{\'a}ndez Arjona, Manuel Montesino. UK: Ramesh Corbarsanellore, Jonathan McFarlane, M. Naeem Akhtar, Neil Paul. Publisher Copyright: {\textcopyright} 2016, The Author(s).",
year = "2017",
month = mar,
day = "1",
doi = "10.1007/s00345-016-1884-5",
language = "English (US)",
volume = "35",
pages = "421--427",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "3",
}